PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ADCT vs. GERN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ADCT and GERN is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

ADCT vs. GERN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). The values are adjusted to include any dividend payments, if applicable.

-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2025February
-43.55%
-36.74%
ADCT
GERN

Key characteristics

Sharpe Ratio

ADCT:

-0.48

GERN:

0.47

Sortino Ratio

ADCT:

-0.25

GERN:

2.18

Omega Ratio

ADCT:

0.97

GERN:

1.26

Calmar Ratio

ADCT:

-0.56

GERN:

0.53

Martin Ratio

ADCT:

-1.31

GERN:

2.82

Ulcer Index

ADCT:

41.34%

GERN:

18.31%

Daily Std Dev

ADCT:

113.73%

GERN:

109.59%

Max Drawdown

ADCT:

-99.08%

GERN:

-98.65%

Current Drawdown

ADCT:

-96.77%

GERN:

-95.59%

Fundamentals

Market Cap

ADCT:

$159.54M

GERN:

$1.76B

EPS

ADCT:

-$2.39

GERN:

-$0.33

Total Revenue (TTM)

ADCT:

$53.48M

GERN:

$29.46M

Gross Profit (TTM)

ADCT:

$47.22M

GERN:

$28.67M

EBITDA (TTM)

ADCT:

-$90.74M

GERN:

-$143.53M

Returns By Period

The year-to-date returns for both stocks are quite close, with ADCT having a -17.09% return and GERN slightly lower at -17.80%.


ADCT

YTD

-17.09%

1M

-18.32%

6M

-43.49%

1Y

-54.79%

5Y*

N/A

10Y*

N/A

GERN

YTD

-17.80%

1M

-18.49%

6M

-36.74%

1Y

59.89%

5Y*

17.03%

10Y*

-0.39%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ADCT vs. GERN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADCT
The Risk-Adjusted Performance Rank of ADCT is 2020
Overall Rank
The Sharpe Ratio Rank of ADCT is 2222
Sharpe Ratio Rank
The Sortino Ratio Rank of ADCT is 2525
Sortino Ratio Rank
The Omega Ratio Rank of ADCT is 2727
Omega Ratio Rank
The Calmar Ratio Rank of ADCT is 1414
Calmar Ratio Rank
The Martin Ratio Rank of ADCT is 1111
Martin Ratio Rank

GERN
The Risk-Adjusted Performance Rank of GERN is 7373
Overall Rank
The Sharpe Ratio Rank of GERN is 6464
Sharpe Ratio Rank
The Sortino Ratio Rank of GERN is 8383
Sortino Ratio Rank
The Omega Ratio Rank of GERN is 7979
Omega Ratio Rank
The Calmar Ratio Rank of GERN is 6969
Calmar Ratio Rank
The Martin Ratio Rank of GERN is 7272
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ADCT vs. GERN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ADC Therapeutics SA (ADCT) and Geron Corporation (GERN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ADCT, currently valued at -0.48, compared to the broader market-2.000.002.004.00-0.480.47
The chart of Sortino ratio for ADCT, currently valued at -0.25, compared to the broader market-4.00-2.000.002.004.00-0.252.18
The chart of Omega ratio for ADCT, currently valued at 0.97, compared to the broader market0.501.001.502.000.971.26
The chart of Calmar ratio for ADCT, currently valued at -0.56, compared to the broader market0.002.004.006.00-0.560.98
The chart of Martin ratio for ADCT, currently valued at -1.31, compared to the broader market-10.000.0010.0020.0030.00-1.312.82
ADCT
GERN

The current ADCT Sharpe Ratio is -0.48, which is lower than the GERN Sharpe Ratio of 0.47. The chart below compares the historical Sharpe Ratios of ADCT and GERN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
-0.48
0.47
ADCT
GERN

Dividends

ADCT vs. GERN - Dividend Comparison

Neither ADCT nor GERN has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ADCT vs. GERN - Drawdown Comparison

The maximum ADCT drawdown since its inception was -99.08%, roughly equal to the maximum GERN drawdown of -98.65%. Use the drawdown chart below to compare losses from any high point for ADCT and GERN. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-96.77%
-42.83%
ADCT
GERN

Volatility

ADCT vs. GERN - Volatility Comparison

ADC Therapeutics SA (ADCT) has a higher volatility of 18.26% compared to Geron Corporation (GERN) at 12.18%. This indicates that ADCT's price experiences larger fluctuations and is considered to be riskier than GERN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%SeptemberOctoberNovemberDecember2025February
18.26%
12.18%
ADCT
GERN

Financials

ADCT vs. GERN - Financials Comparison

This section allows you to compare key financial metrics between ADC Therapeutics SA and Geron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab